ALB and neoplasm: Given that the progression of CRC is dependent on both local and systemic inflammatory responses, these indices have been used to develop CRC-specialized screening markers or scoring systems, namely, the single neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR) (13–15), CRC tumor markers (CA19-9 and CEA), modified Glasgow Prognostic Score (mGPS, albumin, and C-reactive protein in serum) (16, 17), systemic inflammation score (SIS, serum albumin, and LMR) (18), and fecal-based testing (19, 20).